Q-omics provides the consensus-scored LIN28A profile across patient tissues and cancer cell-line models. LIN28A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LIN28A is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, LIN28A RNA expression shows 9,046 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, BRCA, and TGCT as cancer lineages where LIN28A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIN28A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIN28A survival associations across molecular data types. LIN28A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIN28A RNA expression–survival associations across cancer types. High LIN28A expression shows unfavorable associations in UCS, KICH, KIRC, BRCA, DLBC and LIHC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UCS as the clearest survival context for LIN28A RNA expression.
This table summarizes LIN28A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 2. The strongest signals are observed in BRCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LIN28A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIN28A shows lower tumor expression in LUAD and higher tumor expression in BRCA, ESCA, COAD and LIHC. The BRCA box plot shows higher LIN28A RNA expression in tumor versus normal tissue (log2 FC = +0.299, t-test p = .002).
This table shows molecular features associated with LIN28A in patient tissues and cancer cell lines. In patient samples, LIN28A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LIN28A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
